|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao YN, Chen GS and Hong SJ: Circulating
MicroRNAs in gynecological malignancies: From detection to
prediction. Exp Hematol Oncol. 3:142014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rooth C: Ovarian cancer: Risk factors,
treatment and management. Br J Nurs. 22:S23–S30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bristow RE, Tomacruz RS, Armstrong DK,
Trimble EL and Montz FJ: Survival effect of maximal cytoreductive
surgery for advanced ovarian carcinoma during the platinum era: A
meta-analysis. J Clin Oncol. 20:1248–1259. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Winter-Roach BA, Kitchener HC and Lawrie
TA: Adjuvant (post-surgery) chemotherapy for early stage epithelial
ovarian cancer. Cochrane Database Syst Rev. 3:CD0047062012.
|
|
6
|
Winter-Roach BA, Kitchener HC and
Dickinson HO: Adjuvant (post-surgery) chemotherapy for early stage
epithelial ovarian cancer. Cochrane Database Syst Rev: CD004706.
2009. View Article : Google Scholar
|
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li D, Liu X, Lin L, Hou J, Li N, Wang C,
Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits
hepatocellular carcinoma growth and correlates with prognosis of
patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mendell JT and Olson EN: MicroRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Resnick KE, Alder H, Hagan JP, Richardson
DL, Croce CM and Cohn DE: The detection of differentially expressed
microRNAs from the serum of ovarian cancer patients using a novel
real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chung YW, Bae HS, Song JY, Lee JK, Lee NW,
Kim T and Lee KW: Detection of microRNA as novel biomarkers of
epithelial ovarian cancer from the serum of ovarian cancer
patients. Int J Gynecol Cancer. 23:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shapira I, Oswald M, Lovecchio J, Khalili
H, Menzin A, Whyte J, Dos Santos L, Liang S, Bhuiya T, Keogh M, et
al: Circulating biomarkers for detection of ovarian cancer and
predicting cancer outcomes. Br J Cancer. 110:976–983. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suryawanshi S, Vlad AM, Lin HM,
Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel
M, Lee T, et al: Plasma microRNAs as novel biomarkers for
endometriosis and endometriosis-associated ovarian cancer. Clin
Cancer Res. 19:1213–1224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng H, Zhang L, Zhao Y, Yang D, Song F,
Wen Y, Hao Q, Hu Z, Zhang W and Chen K: Plasma miRNAs as diagnostic
and prognostic biomarkers for ovarian cancer. PLoS One.
8:e778532013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kan CW, Hahn MA, Gard GB, Maidens J, Huh
JY, Marsh DJ and Howell VM: Elevated levels of circulating
microRNA-200 family members correlate with serous epithelial
ovarian cancer. BMC Cancer. 12:6272012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu N, Zhang J, Cui W, Kong G, Zhang S, Yue
L, Bai X, Zhang Z, Zhang W, Zhang X and Ye L: miR-520b regulates
migration of breast cancer cells by targeting hepatitis B
X-interacting protein and interleukin-8. J Biol Chem.
286:13714–13722. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Meerloo J, Kaspers GJ and Cloos J:
Cell sensitivity assays: The MTT assay. Methods Mol Biol.
731:237–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han ZB, Yang Z, Chi Y, Zhang L, Wang Y, Ji
Y, Wang J, Zhao H and Han ZC: MicroRNA-124 suppresses breast cancer
cell growth and motility by targeting CD151. Cell Physiol Biochem.
31:823–832. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song B, Zhang C, Li G, Jin G and Liu C:
MiR-940 inhibited pancreatic ductal adenocarcinoma growth by
targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu N, Zhang C, Bai C, Han YP and Li Q:
MiR-4782-3p inhibited non-small cell lung cancer growth via USP14.
Cell Physiol Biochem. 33:457–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garcia DM, Baek D, Shin C, Bell GW,
Grimson A and Bartel DP: Weak seed-pairing stability and high
target-site abundance decrease the proficiency of lsy-6 and other
microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grentzmann G, Ingram JA, Kelly PJ,
Gesteland RF and Atkins JF: A dual-luciferase reporter system for
studying recoding signals. RNA. 4:479–486. 1998.PubMed/NCBI
|
|
31
|
Xu XS, Wang L, Abrams J and Wang G:
Histone deacetylases (HDACs) in XPC gene silencing and bladder
cancer. J Hematol Oncol. 4:172011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X
and Song Y: Over-expression of LSD1 promotes proliferation,
migration and invasion in non-small cell lung cancer. PLoS One.
7:e350652012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang W, Kong G, Zhang J, Wang T, Ye L and
Zhang X: MicroRNA-520b inhibits growth of hepatoma cells by
targeting MEKK2 and cyclin D1. PLoS One. 7:e314502012. View Article : Google Scholar : PubMed/NCBI
|
